Estimating the economic costs of antidepressant discontinuation during pregnancy

Canadian Journal of Psychiatry

Volumn 54, Issue 6, 2009, Pages 399-408

  O'Brien, Lisa ^a   Laporte, Audrey ^b   Koren, Gideon ^a,b,c,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Depression; Medical costs; Ontario health insurance plan; Pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD HEALTH CARE; COST CONTROL; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FEMALE; GOVERNMENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MATERNAL CARE; MEDICAL FEE; PREGNANCY; PREGNANT WOMAN; PREMATURITY; PSYCHOTHERAPY; RELAPSE;

EID: 67649277622     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370905400607     Document Type: Article

References (58)

1. World Health Organization. Mental health: depression [Internet]. Geneva (CH): WHO; 2009 [updated 2009; cited 2008 Jan 25]. Available from: http://www.who.int/mental-health/management/depression/definition/en/.
2. Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry. 2001;46(Suppl 1):5S-90S.
3. Canadian Institute for Health Information. Exploring the 70/30 split: how Canada's health care system is financed [Internet]. Ottawa (ON): CIHI; 2005 [cited 2008 Jan 25]. Available from: http://secure.cihi.ca/cihiweb/products/ FundRep-EN.pdf.
4. Macqueen G, Chokka P. Special issues in the management of depression in women. Can J Psychiatry. 2004;49(Suppl 1):27S-40S. (Pubitemid 38506489)
5. Weissman MM, Olfson M. Depression in women: implications for health care research. Science. 1995;269:799-801.
6. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA. 1999;282:1264-1269. (Pubitemid 29468499)
7. Gold LH. Clinical and forensic aspects of postpartum disorders. J Am Acad Psychiatry Law. 2001;29:344-347. (Pubitemid 32938645)
8. Burt VK, Stein K. Epidemiology of depression throughout the female life cycle. J Clin Psychiatry. 2002;63(Suppl 7):9-15. (Pubitemid 34454034)
9. Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am. 2003;26:547-562. (Pubitemid 37175495)
10. Kaplan EM. Antidepressant noncompliance as a factor in the discontinuation syndrome. J Clin Psychiatry. 1997;58(Suppl 7):31-35. (Pubitemid 27305038)
11. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499-507. (Pubitemid 43200344)
12. Gold LH. Psychopharmacologic treatment of depression during pregnancy. Curr Womens Health Rep. 2003;3:236-241. (Pubitemid 38923230)
13. Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol. 1989;160:1107-1111. (Pubitemid 19144468)
14. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49:726-735. (Pubitemid 40100521)
15. Brent RL, Beckman DA. Environmental teratogens. Bull NY Acad Med. 1990;66:123-163. (Pubitemid 20230141)
16. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005;14:823-827. (Pubitemid 43056107)
17. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579-587. (Pubitemid 43209105)
18. Shah CP. Public health and preventive medicine in Canada. Toronto (ON): University of Toronto Press; 1998.
19. Ministry of Health and Long-Term Care. Ontario Health Insurance Plan [Internet]. Toronto (ON): Queen's Printer for Ontario; 2002 [cited 2008 Jan 25]. Available from: http://www.health.gov.on.ca/english/public/program/ohip/ohip- mn.html.
20. Ministry of Finance. Ontario budget 2007 [Internet]. Toronto (ON): Queen's Printer for Ontario; 2007 [cited 2008 Jan 25]. Available from: http://www.fin.gov.on.ca/english/budget/ontariobudgets/2007/papers-all.html.
21. Sanmartin C, Ng E, Blackwell D, et al. Joint Canada/United States Survey of Health, 2002-2003 [Internet]. Ottawa (ON): Statistics Canada; 2004 [cited 2008 Jan 25]. Available from: http://www.cdc.gov/nchs/data/nhis/jcush- analyticalreport.pdf.
22. Statistics Canada. Health Statistics Division. Births 2006 [Internet]. Catalogue no 84F0210X. Ottawa (ON): Minister of Industry; 2008 [cited 2009 Apr 15]. Available from: http://www.statcan.gc.ca/pub/84f0210x/84f0210x2006000-eng. pdf.
23. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004;103:698-709. (Pubitemid 40459031)
24. Pirraglia P, Stafford R, Singer D. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry. 2003;5(4):153-157.
25. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67-74.
26. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci. 2001;26:44-48. (Pubitemid 32185179)
27. Bonari L, Koren G, Einarson TR, et al. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health. 2005;8:214-220. (Pubitemid 41618841)
28. Koopmans GT, Donker MC, Rutten FH. Common mental disorders and use of general health services: a review of the literature on population-based studies. Acta Psychiatr Scand. 2005;111:341-350. (Pubitemid 40604335)
29. Lin E, Goering P. The utilization of physician services for mental health in Ontario. Toronto (ON): Institute for Clinical Evaluative Sciences; 1999.
30. Chan BTB, Schultz SE. Supply and utilization of general practitioner and family physician services in Ontario. Toronto (ON): Institute for Clinical Evaluative Sciences; 2005. [Investigative Report].
31. Watson DE, Heppner P, Roos NP, et al. Population-based use of mental health services and patterns of delivery among family physicians, 1992 to 2001. Can J Psychiatry. 2005;50:398-406.
32. Public Health Agency of Canada. A report on mental illnesses in Canada: October 2002 [Internet]. Ottawa (ON): Health Canada; 2002 [cited 2008 Jan 25]. Available from: http://www.phac-aspc.gc.ca/publicat/miic-mmac/.
33. Chung TK, Lau TK, Yip AS, et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med. 2001;63:830-834. (Pubitemid 32911013)
34. Berkowitz GS, Papiernik E. Epidemiology of preterm birth. Epidemiol Rev. 1993;15:414-443. (Pubitemid 24072637)
35. Halbreich U. The association between pregnancy processes, preterm delivery, low birth weight, and postpartum depressions - the need for interdisciplinary integration. Am J Obstet Gynecol. 2005;193:1312-1322. (Pubitemid 41395098)
36. Orr ST, James SA, Blackmore PC. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol. 2002;156:797-802. (Pubitemid 35215759)
37. Petrou S. The economic consequences of preterm birth during the first 10 years of life. BJOG. 2005;112(Suppl 1):10-15. (Pubitemid 40313974)
38. Schmitt SK, Sneed L, Phibbs CS. Costs of newborn care in California: a population-based study. Pediatrics. 2006;117:154-160. (Pubitemid 46050532)
39. Lewit EM, Baker LS, Corman H, et al. The direct cost of low birth weight. Future Child. 1995;5:35-56.
40. US Environmental Protection Agency - Office of Pollution Prevention and Toxics. Cost of low birth weight. In: US Environmental Protection Agency - Office of Pollution. Cost of illness handbook. [place unknown]: United States Environmental Protection Agency; 2006. Chapter 2.
41. Boulenger S, Nixon J, Drummond M, et al. Can economic evaluations be made more transferable? Eur J Health Econ. 2005;6:334-346.
42. Khawam EA, Laurencic G, Malone DA Jr. Side effects of antidepressants: an overview. Cleve Clin J Med. 2006;73:351-361.
43. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med. 2006;119:719-727.
44. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004;10:2463-2475.
45. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49:871-874.
46. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372-2383. (Pubitemid 40676760)
47. Koren G, Matsui D, Einarson A, et al. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? CMAJ. 2005;172:1457-1459.
48. Gafni A, Goeree R, Myhr TL, et al. Induction of labour versus expectant management for prelabour rupture of the membranes at term: an economic evaluation. TERMPROM Study Group. Term Prelabour Rupture of the Membranes. CMAJ. 1997;157:1519-1525.
49. Ministry of Health and Long-Term Care. Ontario Health Insurance (OHIP) Schedule of Benefits and Fees [Internet]. Toronto (ON): Ontario Ministry of Health and Long-Term Care; 2006 [cited 2008 May 9]. Available from: http://www.health.gov.on.ca/english/providers/program/ohip/sob/sob-mn.html.
50. Marcus SM, Flynn HA, Blow FC, et al. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health (Larchmt). 2003;12:373-380. (Pubitemid 36701614)
51. Minkovitz CS, Strobino D, Scharfstein D, et al. Maternal depressive symptoms and children's receipt of health care in the first 3 years of life. Pediatrics. 2005;115:306-314. (Pubitemid 43193812)
52. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015. (Pubitemid 26338730)
53. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med. 2000;30:89-94. (Pubitemid 30099121)
54. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279:609-610. (Pubitemid 28110208)
55. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-1730. (Pubitemid 32923672)
56. Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry. 2003;48:106-110. (Pubitemid 36402211)
57. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192:932-936. (Pubitemid 40311292)
58. Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry. 2006;67:1280-1284. (Pubitemid 44439703)